MANKIND - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | MANKIND | Market Cap | 1,00,832 Cr. | Current Price | 2,437 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 47.5 | Book Value | 397 ₹ | Dividend Yield | 0.04 % | ROCE | 13.6 % |
| ROE | 13.7 % | Face Value | 1.00 ₹ | DMA 50 | 2,298 ₹ | DMA 200 | 2,276 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 732 Cr. | PAT Prev Qtr | 512 Cr. |
| RSI | 55.3 | MACD | 68.2 | Volume | 4,31,464 | Avg Vol 1Wk | 11,12,134 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 2.34 | Debt to equity | 0.34 |
| 52w Index | 64.5 % | Qtr Profit Var | 207 % | EPS | 49.4 ₹ | Industry PE | 31.6 |
📊 Analysis:
Mankind Pharma (MANKIND) is trading at ₹2,437, above both its 50 DMA (₹2,298) and 200 DMA (₹2,276), showing strong technical support. RSI at 55.3 indicates neutral-to-positive momentum, while MACD at 68.2 confirms bullish bias. Current volume (4.31 lakh) is well below the weekly average (11.1 lakh), reflecting weaker intraday participation. Valuations are stretched (P/E 47.5 vs industry 31.6), but fundamentals remain strong with ROE at 13.7% and ROCE at 13.6%. Intraday trades are favorable with cautious entries near support zones.
💡 Optimal Buy Zone:
₹2,430–₹2,445 if price sustains above VWAP and DMA support.
🎯 Exit Levels:
- Profit-taking: ₹2,470–₹2,490 (near resistance).
- Stop-loss: ₹2,410–₹2,415 (below intraday support).
⏱️ Intraday Exit Strategy:
If already holding, consider exiting when
- RSI dips below 53 intraday.
- Price fails to hold above ₹2,430 support.
- Volume remains weak (<5 lakh) with stagnating price action.
---
### ✅ Positive
- PAT growth from ₹512 Cr. → ₹732 Cr. (+207%).
- EPS at ₹49.4 reflects earnings strength.
- Trading above both DMA 50 and DMA 200.
- DII holdings increased (+1.20%).
- PEG ratio at 2.34, showing growth visibility.
### ⚠️ Limitation
- Valuation premium (P/E 47.5 vs industry 31.6).
- Dividend yield negligible (0.04%).
- FII holdings decreased (-1.10%).
- Volume below weekly average, limiting intraday strength.
### 📉 Company Negative News
- High valuation relative to peers.
- Weak intraday participation despite bullish technicals.
### 📈 Company Positive News
- Strong quarterly profit growth (+207%).
- Technical breakout above DMA levels.
- Sector demand supports earnings visibility.
### 🏭 Industry
- Pharma sector average P/E at 31.6, Mankind trades at a premium.
- Sector outlook supported by healthcare demand and defensive positioning.
### 📌 Conclusion
Mankind Pharma is a solid intraday candidate with bullish technicals and strong fundamentals, though valuations are stretched. Best suited for tactical trades near ₹2,430–₹2,445 with exits around ₹2,470–₹2,490. Maintain strict stop-loss discipline below ₹2,415 to protect against intraday reversals.
This frames MANKIND as a strong intraday trade with bullish technicals but valuation risks. Would you like me to extend this into a swing trade setup with medium-term entry/exit zones and sector overlays?